Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Palmitic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 2/20 | 0.45 |
| ▸ | PPARG known ✓ | P37231 | 7/20 | 0.44 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 5/20 | 0.44 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.44 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.44 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.44 |
| ▸ | PPARD | Q03181 | 7/20 | 0.44 |
| ▸ | PPARA | Q07869 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | TLR2 | O60603 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxine SCHEMBL483437 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Decanoic Acid SCHEMBL30694319 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Palmitic Acid SCHEMBL29361257 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Dodecanoate SCHEMBL29381594 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Palmitic Acid SCHEMBL4798201 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Palmitic Acid SCHEMBL516266 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Azelaic Acid SCHEMBL5981734 | 0.93 | KDM4E (0.71) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Pyridoxine SCHEMBL28806638 | 0.92 | KDM4E (0.73) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Pyridoxine SCHEMBL31514964 | 0.86 | KDM4E (0.77) | ALDH1A1HSD17B10KDM4EHPGDLMNA | |
| Pyridoxine SCHEMBL9168156 | 0.82 | KDM4E (0.80) | ALDH1A1HSD17B10KDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200230162-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2020-07-23 | — | — | US | disclosed |
| US-10624916-B2 | Nutritional formulations using human milk oligosaccharides for modulating inflammation | ABBOTT LABORATORIES (US) | 2020-04-21 | — | — | US | disclosed |
| EP-3469912-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | Abbott Laboratories (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-2934190-B1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LAB (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20160256479-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160106131-A1 | USE OF HMB TO IMPROVE QUALITY OF LIFE FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2016-04-21 | — | — | US | disclosed |
| EP-2934190-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2015-10-28 | — | — | EP | disclosed |
| WO-2015105981-A2 | CONDITIONAL ESSENTIALITY OF HMB | ABBOTT LABORATORIES (US) | 2015-07-16 | — | — | WO | disclosed |
| US-20150119339-A1 | USE OF HMB TO IMPROVE HEALTH OUTCOMES FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2015-04-30 | — | — | US | disclosed |
| WO-2014100696-A1 | NUTRITIONAL FORMULATIONS USING HUMAN MILK OLIGOSACCHARIDES FOR MODULATING INFLAMMATION | ABBOTT LABORATORIES (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-2745708-A1 | Antidepressant effect of ß-hydroxy-ß-methylbutyrate | Abbott Laboratories, Inc. (US) | 2014-06-25 | — | — | EP | disclosed |
| WO-2013188258-A1 | USE OF HMB TO IMPROVE HEALTH OUTCOMES FOR HOSPITALIZED PATIENTS | ABBOTT LABORATORIES (US) | 2013-12-19 | — | — | WO | disclosed |